Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acetophenazine is a typical antipsychotic drug of moderate potency belonging to the phenothiazine class. It is primarily used in the treatment of disorganized and psychotic thinking, including symptoms such as hallucinations and delusions. The drug acts mainly as an antagonist at dopamine D2 receptor in the brain, blocking postsynaptic mesolimbic dopaminergic D1 and D2 receptors. This action helps reduce psychotic symptoms by modulating dopaminergic neurotransmission. Acetophenazine may also depress the release of hypothalamic and hypophyseal hormones and affect basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis by depressing the reticular activating system[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acetophenazine.